OncoTherics has signed a collaboration agreement with the University of Cambridge to progress a series of novel preclinical investigations using OCT1002 in Pancreatic Tumour models.
The investigations will augment OncoTherics formal preclinical studies, providing useful additional information about OCT1002 in Pancreatic Cancer.
No comments:
Post a Comment